Monday, December 23, 2024
HomeTagsDisitamab Vedotin

Disitamab Vedotin

RemeGen’s Telitacicept and Disitamab Vedotin Enter China’s National Reimbursement Drug List for SLE and Gastric Cancer Treatment

RemeGen Co., Ltd., a commercial-ready biotechnology company, announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics